Introduction: Chylomicronemia syndrome (CS) is a rare disorder characterized by a high level of triglycerides in plasma. We present a case of a pregnant woman with a severe acute pancreatitis (AP) affected by a CS.

Case: A 38-year-old gravida 2, para 0 with an uneventful course of pregnancy was referred with an AP at 37 0/7 weeks of gestation. This diagnosis was made from a nearby hospital where the chemical analysis showed elevated pancreatic enzymes with significant hypertriglyceridemia. Because of a pathological fetal heart tracing a caesarean delivery was performed. The APGAR score of the female newborn was 5/8/8 at 1, 5 and 10 minutes, respectively. The pH from the umbilical cord were 7.26 (artery) and 7.59 (vein). Once transferred to our intensive care unit a computer tomography scan confirmed an onset of a necrotizing AP. A conservative treatment was tried without success. For this reason a surgical debridement of the infected and necrosic parts was performed. After a long hospitalisation the patient could be dismissed after 2.5 months in good general condition.

Discussion: Lipid profile changes in normal pregnancy are characterized by an elevation of total plasma cholesterol and triglyceride levels. This is normally caused by an increased liver synthesis of triglycerides in response to elevated estrogen levels. When a CS is diagnosed the main goal is to maintain fasting triglyceride levels at less than 500 mg/dL to reduce the risk for AP.

Conclusion: Practitioners have an important role in evaluating chylomicronemic patients and implementing therapeutic lifestyle and pharmacoeutic interventions aimed to reduce the risk for AP.
Introduction

Chylomicronemia syndrome is a rare familial genetic disorder characterized by an abnormal high level of triglycerides (>11.3 mmol/L) and a massive accumulation of chylomicrons. This condition can lead to the development of hepatosplenomegaly, occasionally lipemia retinalis, eruptive xanthoma and abdominal symptoms [1–2]. The incidence of this disorder is one in one million and is caused by a gene mutation of an enzyme called lipoprotein lipase or apoprotein C-II. The deficiency of this enzyme, normally found in fat and muscle, determines the inability to reduce fatty acids [2–3]. In these cases one of the most feared potentially life threatening complications is a severe acute pancreatitis (AP). The incidence of AP is approximately 5% and the mortality, in severe cases, can reach 39% [4–5]. During a pregnancy the woman undergoes profound and reversible anatomical and physiological change which also involves the lipid metabolism. We present a very rare case of a pregnant woman with a severe AP affected by a chylomicronemia syndrome characterized by massive high levels of triglycerides in blood.

Case

A 38-year-old gravida 2, para 0 with an uneventful course of pregnancy and a history of a hypertriglyceridemia (HTG) of unknown origin for over 20 years was referred at 37 0/7 weeks of gestation to a nearby hospital with sudden and persistent abdominal pain. The chemical analysis excluded a HELLP syndrome but showed elevated pancreatic enzymes (lipase 1690 U/L, amylase 1533 U/L) with significant HTG (triglyceride 155 mmol/L). A diagnosis of acute pancreatitis was made and because of decreased coagulation values the patient was transferred to our hospital. At admission, a pathological fetal heart tracing associated with a breech presentation was detected and a caesarean delivery was performed immediately. The Apgar score of the female newborn was 5/8/8 at 1, 5 and 10 minutes, with a birth weight of 2720 g. The pH from the umbilical cord were 7.26 (artery) and 7.59 (vein). Once transferred to our intensive care unit a computer tomography scan confirmed an onset of an AP associated with a massive abdominal fluid collection (Fig. 1). An acute pancreatitis secondary to HTG was considered. A conservative treatment with systemic antibiotics (imipenem), fluid replacement and parenteral nutrition was tried without success. For this reason a surgical debridement was performed and an infected necrosis of the pancreas was detected. The operation was performed via an upper midline access. Once localized the debrided necrotic tissue. During the hospitalization the severe hypertriglyceridemia-induced pancreatitis was caused by a chylomicronemia syndrome (not known by the patient) associated by oestrogen exposure due to the pregnancy. After a long-lasting hospitalisation with cessation of oral intake and a continuous postoperative lavage the patient could be discharged home after 2.5 months in good general condition.

Discussion

During pregnancy the lipid metabolism changes, characterized by an elevation of total plasma cholesterol and triglyceride levels. This is normally caused by an increased liver synthesis of triglycerides in response to elevated estrogen levels. These changes are important for the fetal-maternal needs. This high level of triglyceride concentration in the serum permits the mother to spare glucose for the fetus and allows, thanks to elevated LDL cholesterol levels, the placental steroidogenesis [6].

Acute pancreatitis is a life-threatening condition caused by different agents [7]. HTG, after alcohol and gallstones, is considered the third most common cause of AP (Table 1). The identification of risk factors, like HTG, plays an important role in preventing AP. This disease has not yet not occurred in patients with triglyceride levels under 5.6 mmol/L, but the risk of AP increases above this value and markedly over 11.3 mmol/L [8].

Pregnancy-induced HTG has been found to be responsible for up to 56% of cases of AP. In an uncomplicated pregnancy the serum triglycerides rarely exceed 3.3 mmol/L but if they do so, like in our case, the cause can be an unrecognized genetic disorder that elevates the concentration of triglycerides, predisposing the pregnant woman for AP [9].

Our patient had a history of undiagnosed cause of HTG for over 20 years. In this case the pregnancy had probably acted as triggering factor that determined an exacerbation of a pre-existing.

Table 1: Common causes of acute pancreatitis.

- Alcohol
- Gallstones
- Metabolic disorders
- Abdominal trauma
- Penetrating ulcers
- Malignancy
- Drugs
- Infections
- Structural abnormalities
lipid abnormality determining a markedly elevation of triglycerides in blood up to 155 mmol/L. The result was severe onset of AP with an increased risk of mortality for both mother and fetus. Preventive measures in patients affected by a chylomicronemia syndrome, especially before pregnancy occurs, play an important role to avoid an AP. When triglyceride levels are above 5.6 mmol/L a nonpharmacological treatment with weight loss, aerobic exercise, avoidance of sugars and strict glycemic control is considered sufficient to minimize the risk of AP [10,11]. On the contrary when the triglyceride level exceeds 11.3 mmol/L, a pharmacological treatment for example with gemfibrozil must be started as soon as possible. This therapy is often required during the third trimester of pregnancy, a period during which the serum levels of triglycerides are normally at their highest [12,13].

When an AP caused by HTG is detected, the therapy resembles that of pancreatitis of other origin, but differs in terms of the severity of the disease. In a mild AP, supportive care including pain control, intravenous fluids, correction of electrolyte and metabolic abnormalities is suggested. Intravenous insulin is a low-cost and effective good alternative treatment in HTG-induced pancreatitis during pregnancy [9]. This differs from cases of a severe AP where the mortality rate is around 39% and monitoring in an intensive care unit with support of renal, circulatory, pulmonary and hepatobiliary function with cessation of oral intake is strictly recommended. Fluid replacement and antibiotics like imipenem are usually administered to avoid a vascular leak syndrome in case of a necrotizing pancreatitis [14].

**Conclusion**

Early diagnosis of chylomicronemia syndrome is the key component to avoid severe complications and improve pregnancy outcome. Practitioners have an important role in evaluating chylomicronemic patients and implementing therapeutic lifestyle and pharmacologic interventions aimed to reduce the risk of AP.